Alexander Spektor, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Oncology | 6 | 2019 | 563 | 0.520 |
Why?
|
Genomic Instability | 3 | 2017 | 709 | 0.500 |
Why?
|
Palliative Care | 9 | 2022 | 3599 | 0.500 |
Why?
|
Chromosomes | 1 | 2017 | 579 | 0.470 |
Why?
|
Microtubule-Associated Proteins | 4 | 2009 | 1075 | 0.360 |
Why?
|
Nucleotidyltransferases | 2 | 2024 | 242 | 0.330 |
Why?
|
Chromosome Breakage | 2 | 2020 | 159 | 0.290 |
Why?
|
Mitosis | 2 | 2024 | 1187 | 0.280 |
Why?
|
Neoplasms | 11 | 2022 | 22142 | 0.280 |
Why?
|
Phosphoproteins | 5 | 2024 | 2444 | 0.250 |
Why?
|
Cyclin B1 | 1 | 2024 | 57 | 0.240 |
Why?
|
Clinical Clerkship | 3 | 2015 | 564 | 0.230 |
Why?
|
Centrioles | 3 | 2009 | 80 | 0.230 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2024 | 111 | 0.220 |
Why?
|
DNA Damage | 3 | 2020 | 2443 | 0.220 |
Why?
|
Tattooing | 1 | 2023 | 57 | 0.220 |
Why?
|
Radiosurgery | 2 | 2023 | 1339 | 0.220 |
Why?
|
Cilia | 1 | 2007 | 495 | 0.210 |
Why?
|
Cell Cycle Proteins | 3 | 2009 | 3446 | 0.190 |
Why?
|
Multiprotein Complexes | 2 | 2024 | 1112 | 0.160 |
Why?
|
Bone Diseases | 1 | 2022 | 418 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 328 | 0.150 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4909 | 0.140 |
Why?
|
Lymphopenia | 1 | 2018 | 282 | 0.130 |
Why?
|
Bone Neoplasms | 2 | 2019 | 2527 | 0.130 |
Why?
|
Cytokinesis | 2 | 2007 | 169 | 0.130 |
Why?
|
Micronuclei, Chromosome-Defective | 1 | 2015 | 38 | 0.120 |
Why?
|
Radiotherapy | 2 | 2018 | 1500 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1057 | 0.110 |
Why?
|
Immune System | 1 | 2019 | 792 | 0.110 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2018 | 424 | 0.110 |
Why?
|
Brain Neoplasms | 3 | 2019 | 9025 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8519 | 0.110 |
Why?
|
Curriculum | 3 | 2015 | 3741 | 0.100 |
Why?
|
Spinal Neoplasms | 1 | 2019 | 703 | 0.100 |
Why?
|
Life Expectancy | 1 | 2019 | 1242 | 0.100 |
Why?
|
Indoles | 1 | 2019 | 1830 | 0.100 |
Why?
|
Pain | 3 | 2022 | 5072 | 0.090 |
Why?
|
Pain Measurement | 1 | 2020 | 3549 | 0.090 |
Why?
|
Immunity, Innate | 2 | 2024 | 3044 | 0.090 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13386 | 0.090 |
Why?
|
Polyploidy | 2 | 2007 | 119 | 0.090 |
Why?
|
Program Evaluation | 2 | 2015 | 2489 | 0.090 |
Why?
|
Melanoma | 2 | 2019 | 5694 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2019 | 2871 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3875 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1892 | 0.080 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 16954 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5301 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4872 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7851 | 0.070 |
Why?
|
Career Choice | 1 | 2014 | 757 | 0.070 |
Why?
|
Precipitin Tests | 1 | 2007 | 812 | 0.070 |
Why?
|
Mutation | 6 | 2024 | 30004 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5366 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1072 | 0.070 |
Why?
|
Centrosome | 1 | 2007 | 209 | 0.070 |
Why?
|
Chromosome Segregation | 2 | 2018 | 235 | 0.060 |
Why?
|
NIH 3T3 Cells | 1 | 2007 | 667 | 0.060 |
Why?
|
Humans | 28 | 2024 | 761222 | 0.060 |
Why?
|
Students, Medical | 2 | 2015 | 1940 | 0.060 |
Why?
|
Coenzymes | 1 | 2024 | 101 | 0.060 |
Why?
|
Cell Cycle | 2 | 2009 | 2926 | 0.060 |
Why?
|
DNA | 1 | 2017 | 7189 | 0.060 |
Why?
|
Cell Line | 4 | 2015 | 15545 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2018 | 10423 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 2 | 2009 | 3726 | 0.050 |
Why?
|
Green Fluorescent Proteins | 1 | 2007 | 2062 | 0.050 |
Why?
|
HeLa Cells | 2 | 2024 | 3073 | 0.050 |
Why?
|
RNA Interference | 2 | 2007 | 2816 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 3163 | 0.050 |
Why?
|
Cell Division | 1 | 2009 | 4451 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2006 | 1067 | 0.050 |
Why?
|
S Phase | 2 | 2015 | 423 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4642 | 0.050 |
Why?
|
Quality of Life | 2 | 2020 | 13367 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6919 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3593 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2023 | 1655 | 0.040 |
Why?
|
Animals | 7 | 2024 | 168089 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5809 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2017 | 4251 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11733 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 613 | 0.040 |
Why?
|
Actomyosin | 1 | 2020 | 109 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 455 | 0.040 |
Why?
|
raf Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
Exodeoxyribonucleases | 1 | 2020 | 191 | 0.040 |
Why?
|
Mechanical Phenomena | 1 | 2020 | 142 | 0.040 |
Why?
|
Workflow | 1 | 2023 | 850 | 0.040 |
Why?
|
Health Facilities | 1 | 2023 | 575 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4574 | 0.040 |
Why?
|
Program Development | 2 | 2015 | 1294 | 0.040 |
Why?
|
RNA, Small Interfering | 1 | 2007 | 3412 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5321 | 0.040 |
Why?
|
Cultural Characteristics | 1 | 2019 | 250 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2024 | 1149 | 0.040 |
Why?
|
Death | 1 | 2022 | 677 | 0.040 |
Why?
|
Mice | 5 | 2024 | 81330 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 636 | 0.030 |
Why?
|
Referral and Consultation | 2 | 2020 | 3608 | 0.030 |
Why?
|
Internship and Residency | 1 | 2017 | 5885 | 0.030 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 2452 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2018 | 781 | 0.030 |
Why?
|
Morals | 1 | 2019 | 289 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1226 | 0.030 |
Why?
|
Interferon Type I | 1 | 2019 | 557 | 0.030 |
Why?
|
Protein Binding | 2 | 2024 | 9297 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1217 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2024 | 2194 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 1602 | 0.030 |
Why?
|
Dermatitis | 1 | 2017 | 202 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2017 | 390 | 0.030 |
Why?
|
Spirituality | 1 | 2019 | 429 | 0.030 |
Why?
|
Proteome | 1 | 2024 | 1856 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2022 | 80675 | 0.030 |
Why?
|
Models, Molecular | 1 | 2024 | 5406 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1089 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 901 | 0.030 |
Why?
|
Aged | 7 | 2020 | 169292 | 0.030 |
Why?
|
Female | 10 | 2024 | 392552 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58952 | 0.030 |
Why?
|
Chicago | 1 | 2014 | 254 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1726 | 0.030 |
Why?
|
Male | 9 | 2022 | 360703 | 0.020 |
Why?
|
Mice, Nude | 1 | 2018 | 3606 | 0.020 |
Why?
|
Kidney | 1 | 2007 | 7033 | 0.020 |
Why?
|
Middle Aged | 7 | 2020 | 220858 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9458 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 6125 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54437 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2015 | 1125 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3024 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2425 | 0.020 |
Why?
|
Advance Care Planning | 1 | 2017 | 697 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2813 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2024 | 14392 | 0.020 |
Why?
|
G2 Phase | 1 | 2009 | 136 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 1155 | 0.020 |
Why?
|
Signal Transduction | 2 | 2024 | 23419 | 0.020 |
Why?
|
Educational Measurement | 1 | 2015 | 1250 | 0.020 |
Why?
|
Colitis | 1 | 2017 | 1234 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4423 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 2024 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20118 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11119 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22128 | 0.020 |
Why?
|
Neutrophils | 1 | 2018 | 3763 | 0.020 |
Why?
|
Calmodulin | 1 | 2006 | 217 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7804 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5778 | 0.020 |
Why?
|
Terminal Care | 1 | 2017 | 1760 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2756 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9417 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2022 | 64681 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8837 | 0.010 |
Why?
|
Adult | 4 | 2020 | 221120 | 0.010 |
Why?
|
Molecular Weight | 1 | 2006 | 2171 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5665 | 0.010 |
Why?
|
Apoptosis | 1 | 2018 | 9478 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9327 | 0.010 |
Why?
|
Protein Transport | 1 | 2006 | 1958 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3778 | 0.010 |
Why?
|
United States | 2 | 2017 | 72341 | 0.010 |
Why?
|
Clinical Competence | 1 | 2014 | 4788 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13632 | 0.010 |
Why?
|
Gene Expression | 1 | 2006 | 7571 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16575 | 0.000 |
Why?
|